...
首页> 外文期刊>BMC Nephrology >Soluble TWEAK independently predicts atherosclerosis in renal transplant patients
【24h】

Soluble TWEAK independently predicts atherosclerosis in renal transplant patients

机译:可溶性调整独立预测肾移植患者的动脉粥样硬化

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Cardiovascular risk is increased in the early stages of chronic kidney disease (CKD) and also found to be ongoing in renal transplant (Rtx) patients. As a sign of atherosclerosis, increased carotid intima-media thickness (CIMT) has been widely accepted as a strong predictor of cardiovascular disease (CVD) and mortality in CKD patients. A novel markers, soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and neutrophil-to-lymphocyte ratio (NLR) were introduced as potential markers in inflammatory disorders including CKD. The role of Rtx in terms of atherogenesis is still unclear. We aimed to investigate the relationship between sTWEAK, NLR and CIMT in Rtx patients without overt CVD and to compare these results with those obtained from healthy subjects. Methods Cross-sectional analysis in which CIMT measurements, NLR and serum TWEAK levels were assessed in 70 Rtx patients (29 females; mean age, 40.6?±?12.4 years) and 25 healthy subjects (13 females, mean age; 37.4±8.8 years). Results sTWEAK levels were significantly decreased (p=0.01) and hs-CRP, NLR and CIMT levels of Rtx patients were significantly increased compared to healthy subjects (p Conclusion sTWEAK might have a role in the pathogenesis of ongoing atherosclerosis in Rtx patients.
机译:背景技术在慢性肾脏疾病(CKD)的早期阶段增加了心血管风险,并且还发现在肾移植(RTX)患者中持续。作为动脉粥样硬化的迹象,增加的颈动脉内膜介质厚度(CIMT)被广泛被认为是CKD患者的心血管疾病(CVD)和死亡率的强烈预测因子。一种新型标记,可溶性肿瘤坏死因子状弱凋亡(STWEAK)和中性粒细胞对淋巴细胞比(NLR)的弱诱导剂被引入炎症障碍中的潜在标志物,包括CKD。 RTX在α-血肿方面的作用仍然不清楚。我们旨在探讨在没有公开CVD的RTX患者中StWeak,NLR和CIMT之间的关系,并将这些结果与从健康受试者中获得的那些进行比较。方法在70 rTX患者中评估了CIMT测量,NLR和血清调节水平的横截面分析(29例;平均年龄,40.6?±12.4岁)和25名健康受试者(13名女性,平均年龄; 37.4±8.8岁)。结果STWEAK水平显着降低(P = 0.01),与健康受试者相比,HS-CRP,NLR和CIMT水平的RTX患者的患者显着增加(P结束STWeak可能在RTX患者的持续动脉粥样硬化的发病机制中作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号